Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period

Journal of Infectious Diseases

Volumn 208, Issue 3, 2013, Pages 423-431

  Armah, George E ^a   Kapikian, Albert Z ^b   Vesikari, Timo ^c   Cunliffe, Nigel ^d   Jacobson, Robert M ^e   Burlington, D Bruce ^f   Ruiz, Leonard P ^g  

^a UNIVERSITY OF GHANA   (Ghana)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e MAYO CLINIC   (United States)

^f International Medica Foundation ^*

^g International Medica Foundation   (United States)

Author keywords

attenuated; diarrhea; gastroenteritis; Ghana; humans; infant; infantile; randomized controlled trial; rotavirus; rotavirus infections; rotavirus vaccines; vaccines

Indexed keywords

PLACEBO; REASSORTANT ROTAVIRUS TETRAVALENT VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; EYE DISEASE; FEMALE; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GHANA; HUMAN; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; INTENTION TO TREAT ANALYSIS; MALARIA; MALE; NEWBORN; NEWBORN PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RETROVIRUS INFECTION; RURAL AREA; SEROTYPE; SKIN DISEASE; VIRAL GASTROENTERITIS;

EID: 84880239202     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit174     Document Type: Article

References (48)

1. Tate J, Burton A, Boschi-Pinto C, et al. 2008 estimate of worldwide ro-tavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2011; 12:136-41.
2. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23:937-43.
3. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757-63.
4. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010; 125:e199-207.
5. Staat MA, Payne DC, Donauer S, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics 2011; 128:e267-75.
6. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-98.
7. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:615-23.
8. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606-14.
9. Clark HF, Marcello AE, Lawley D, Reilly M, DiNubile MJ. Unexpectedly high burden of rotavirus gastroenteritis in very young infants. BMC Pediatr 2010; 10:40.
10. Gladstone BP, Ramani S, Mukhopadhya I, et al. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 2011; 365:337-46.
11. Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999; 48:1007.
12. Kapikian AZ. A rotavirus vaccine for prevention of severe diarrhoea of infants and young children: development, utilization and withdrawal. Novartis Found Symp 2001; 238:153-71; discussion 171-9.
13. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine.[Erratum appears in N Engl J Med 2001 May 17;344(20):1564 Note: Livingood, JR [corrected to Livengood, JR]]. N Engl J Med 2001; 344:564-72.
14. Murphy BR, Morens DM, Simonsen L, Chanock RM, La Montagne JR, Kapikian AZ. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 2003; 187:1301-8.
15. Murphy TV, Smith PJ, Gargiullo PM, Schwartz B. The first rotavirus vaccine and intussusception: epidemiological studies and policy decisions. J Infect Dis 2003; 187:1309-13.
16. Kapikian A. History of rotavirus vaccines part I: RotaShield. In: Plotkin S, ed. History of vaccine development. New York: Springer 2011:285-314.
17. Patel MM, Lopez-Collada VR, Bulhoes MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011; 364:2283-92.
18. Escolano S, Farrington CP, Hill C, Tubert-Bitter P. Intussusception after rotavirus vaccination-spontaneous reports. N Engl J Med 2011; 365:2139.
19. Therapeutic Goods Administration, Australian Government, Department of Health and Ageing. Rotavirus vaccination and risk of intussusception: A report of TGA's investigation of a possible safety signal. http://www.tga.gov.au/ safety/alerts-medicine-rotavirus-110225.htm. Accessed 8 May 2013.
20. Buttery JP, Danchin MH, Lee KJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011; 29:3061-6.
21. Oberle DF, Jenke AC, von Kries R, Mentzer D, Keller-Stanislawski B. Rotavirus vaccination: a risk factor for intussusception? (Abstract). http://www.kenes.com/espid2012/abstracts/pdf/780.pdf. Accessed 8 May 2013.
22. Velazquez FR, Colindres RE, Grajales C, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J 2012; 31:736-44.
23. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005; 192 (Suppl 1):S36-43.
24. Kapikian AZ, Simonsen L, Vesikari T, et al. A hexavalent human rotavi-rus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J Infect Dis 2005; 192 (Suppl 1): S22-9.
25. Rothman KJ, Young-Xu Y, Arellano F. Age dependence of the relation between reassortant rotavirus vaccine (RotaShield) and intussusception. J Infect Dis 2006; 193:898; author reply 898-9.
26. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
27. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a penta-valent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33.
28. Gargiullo PM, Murphy TV, Davis RL. Is there a safe age for vaccinating infants with tetravalent rhesus-human reassortant rotavirus vaccine? J Infect Dis 2006; 194:1793-4.
29. Tate JE, Simonsen L, Viboud C, et al. Trends in intussusception hospi-talizations among US infants, 1993-2004: implications for monitoring the safety of the new rotavirus vaccination program. Pediatrics 2008; 121:e1125-32.
30. Desai R, Parashar UD, Lopman B, et al. Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America. Clin Infect Dis 2012; 54:1397-405.
31. Vesikari T, Karvonen AV, Majuri J, et al. Safety, efficacy, and immuno-genicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis 2006; 194:370-6.
32. Tate JE, Curns AT, Cortese MM, et al. Burden of acute gastroenteritis hospitalizations and emergency department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now-withdrawn rotashield vaccine. Pediatrics 2009; 123:744-9.
33. Cunliffe NA, Ngwira BM, Dove W, et al. Epidemiology of rotavirus infection in children in Blantyre, Malawi, 1997-2007. J Infect Dis 2010; 202 (Suppl):S168-74.
34. Halsey N, Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. B World Health Organ 1985; 63:1151-1169.
35. RotaShield(R) [package insert]. Philadelphia, PA: Wyeth Ayerst Laboratories, 1998.
36. U.S. Central Intelligence Agency. Ghana. https://www.cia.gov/library/ publications/the-world-factbook/geos/gh.html. Accessed 8 May 2013.
37. Ghana Statistical Service, Ministry of Health (MOH) (Ghana), Macro International Inc. Ghana Demographic and Health Survey, 2008. http://www.healthmetricsandevaluation.org/ghdx/record/ghana-demographic-and- health-survey-2008. Accessed 8 May 2013.
38. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259-67.
39. Gentsch JR, Glass RI, Woods P, et al. Identification of group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol 1992; 30:1365-73.
40. Gouvea V, Glass RI, Woods P, et al. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. J Clin Microbiol 1990; 28:276-82.
41. Ward RL, Bernstein DI, Shukla R, et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis 1989; 159:79-88.
42. Dagan R, Kassis I, Sarov B, et al. Safety and immunogenicity of oral tet-ravalent human-rhesus reassortant rotavirus vaccine in neonates. Pediatr Infect Dis J 1992; 11:991-6.
43. Vesikari T, Karvonen A, Forrest BD, Hoshino Y, Chanock RM, Kapi-kian AZ. Neonatal administration of rhesus rotavirus tetravalent vaccine. Pediatr Infect Dis J 2006; 25:118-22.
44. Ruuska T, Vesikari T, Delem A, Andre FE, Beards GM, Flewett TH. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. Scand J Infect Dis 1990; 22:269-78.
45. Meeting of the Strategic Advisory Group of Experts on immunization, April 2012-conclusions and recommendations. Wkly Epidemiol Rec 2012; 87:201-16.
46. Bines JE, Ivanoff B. Acute intussusception in infants and children-Incidence, clinical presentation and management: s global perspective. Vaccines and Biologicals. Geneva: World Health Organization, 2002: 98.
47. Enweronu-Laryea CC, Sagoe KWC, Glover-Addy H, Asmah RH, Mingle JA, Armah GE. Prevalence of severe acute rotavirus gastroenteritis and intussusceptions in Ghanaian children under 5 years of age. J Infect Dev Ctries 2012; 6:148-55.
48. Lee BY, Assi TM, Rookkapan K, et al. Maintaining vaccine delivery following the introduction of the rotavirus and pneumococcal vaccines in Thailand. PLoS ONE [Electronic Resource]. 2011;6:e24673.